Article Text

other Versions

PDF
Prevention of type 2 diabetes—where do you draw the line?

Statistics from Altmetric.com

Choosing a pharmacological management strategy for people with type 2 diabetes is controversial because much of the evidence for therapeutic interventions relies on surrogate outcomes.1 Recently however, the way that pre-diabetes is identified has been challenged,2 possibly undermining an NHS England programme to reduce the health burden of the disease.3 At the heart of this lies a debate over the meaning and utility of terms such as non-diabetic hyperglycaemia and pre-diabetes, and unanswered questions over the place of drug treatment.4

Healthier you: the NHS Diabetes Prevention Programme was announced in 2015 with the aim of significantly reducing or delaying the …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.